Strategic partnerships Source BioScience has a history of expanding through acquisitions and collaborations, including recent integration with Clinical Laboratories Ltd and partnerships with Stilla Technologies. This presents opportunities to pitch bundled diagnostics services, co-marketed bioinformatics offerings, and joint go-to-market strategies with digital PCR and multi-omic capabilities.

NHS and private networks With over 85 NHS Trusts supported and a broad private healthcare network, there is strong demand for scalable digital pathology, AI-assisted workflows, and rapid turnaround genomics testing. Sales opportunities exist in expanding digital pathology adoption, LIMS integration, and trusted diagnostic reporting across large public healthcare networks.

Multi-omic leadership Source Genomics offers Sanger sequencing, NGS, proteomics, and spatial transcriptomics among others. This breadth enables upsell across customers needing end-to-end capabilities, rapid data delivery, and bespoke analytical pipelines, including bioinformatics services and advanced omics for translational research.

Digital pathology leverage The company emphasizes AI-enabled digital pathology and workflow digitisation with Source HIVE LIMS integration. This is a compelling angle for hospitals seeking to increase reporting capacity, reduce turnaround times, and optimize pathology department efficiency via AI-assisted diagnostics.

Global growth signals Recent corporate activity, including asset sales and partnerships, signals a strategic repositioning and potential for cross-border collaborations, regional expansions, and new service line introductions. A sales approach can frame connectivity to broader healthcare ecosystems and geographic servicing capabilities.